HIPEC for colorectal peritoneal metastases

Cancer shared this article with you from Inoreader [Comment] HIPEC for colorectal peritoneal metastases Via The Lancet Oncology The treatment of patients with metastatic colorectal cancer has changed profoundly over the past 25 years. In 1995, fluorouracil was the only active chemotherapy available for the disease, and long-term survival (ie, for at least 5 years) was rarely achieved with chemotherapy alone.1 Only patients with surgically resectable liver and lung metastases had a reasonable chance of long-term survival.1 Since then, more chemotherapeutic drugs have been approved, and median survival has increased to 2–3 years (from around 6–12 months), with 20–25% of patients surviving for at least 5 years. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.